Hornet Therapeutics reports first data of EBV-triggered disease blocker

Hornet Therapeutics Ltd will use a US$5m seed financing to launch clinical tests of its IDO1 blocker HTX-201within the next 12 to 18 months to target post-transplant lymphoproliferative disease.

AstraZeneca puts step into lucrative obesity market

Swiss obesity start up SixPeaks Bio AG has made a good start, announcing a US$30m Series A financing led by Versant Ventures and a US$80m biobucks partnership with AstraZeneca plc.

AstraZeneca puts step into obesity market

Swiss obesity start up SixPeaks Bio AG has made a good start, announcing a US$30m Series A financing led by Versant Ventures and a US$80m biobucks partnership with AstraZeneca plc.

Seed financing for Cellugy A/S

Danish industrial biotechnology startup Cellugy raises €4,9m with the ambition to replace petrochemicals in personal care products.<br /><br /><br />

Obesity: Roche with first clinical data after US$2.7bn deal

Obesity candidate CT-388, which Genentech added to Roche's pipeline with the acquisition of Carmot Therapeutics, is at least not a disappointment, according to new trial data.<br /><br />

First dog snack from microbial protein

German-Portuguese biotech start-up MicroHarvest GmbH and a Munich-based pet food manufacturer want to launch the first dog snack made by single cell protein.<br /><br /><br />

AC Immune and Takeda ink US$2.1bn biobucks deal

AC Immune and Takeda have inked an exclusive option license agreement for ACI-24.060, a first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression. <ul><li></li></ul>